Working... Menu
Trial record 2 of 195 for:    Hemorrhage AND SAH

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa (EPO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00626574
Recruitment Status : Terminated (This study is terminated as a result of data from a study that showed increased mortality in stroke patients.)
First Posted : February 29, 2008
Results First Posted : October 29, 2012
Last Update Posted : July 31, 2018
Ortho Biotech, Inc.
Information provided by (Responsible Party):
Enrico Camporesi, University of South Florida

Brief Summary:

This is a prospective, randomized, double-blinded, placebo controlled pilot safety study that will enroll a total of twenty subjects. Subjects will be adults (30-75) who have sustained a SAH secondary to cerebral aneurysm rupture and who present with minimal neurological symptoms. All subjects will have a Hemoglobin less than or equal to 12 g/dL within 24 hours prior to study entry and undergo operative aneurismal clipping. Subjects will be randomized into two groups, ten subjects receiving the drug and ten subjects receiving the placebo. The subjects will receive three intravenous injections of study drug or placebo, once before undergoing operative aneurysmal clipping (study Day 1) and again for two additional days (study Day 2 and study Day 3).

There are 3 phases to this trial:

Screening Phase - patients will present with Subarachnoid hemorrhage (SAH) and prepped for surgery within 36 hours Treatment Phase - first pre-operative dose before surgery (Study Day 1), post-operative (Study Days 2 and 3) Follow-up Phase- Study Day 4 through discharge, 6-7 week follow-up Primary Objective: To determine the safety of administering intravenous doses of Procrit® once daily for three consecutive days to patients with aneurysmal SAH before and after vascular clipping by comparing the incidence of thrombotic events, hemoglobin and 6-7 week mortality between the Procrit® and placebo groups. Secondary Objectives: To determine if administration of Procrit® prior to aneurysm clipping reduces the incidence of vasospasm following a SAH event treated by vascular clipping. To determine if Procrit® administration prior to aneurysm clipping in patients with Aneurysmal SAH will improve neurological assessment scores in the post-SAH/post-clipping time period. To determine the feasibility of organizing a larger, randomized study to explore the neuroprotective effect of Procrit® in patients with Aneurysmal SubArachnoid Hemorrhage (SAH) when Procrit® is administered prior to surgical clipping of the aneurysm.

It is hypothesized that Procrit will provide a significant level of neuroprotection in the brain after an SAH event as a result of reduced cell death, as well as a reduced amount of vasospasm activity and delayed cerebral ischemia which can occur as a result of SAH. These factors may contribute to improved neurological functioning scores when compared to the placebo treated patients.

Condition or disease Intervention/treatment Phase
Subarachnoid Hemorrhage Drug: Epoetin alfa Drug: Saline Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blinded, Placebo Controlled, Pilot Study to Evaluate the Safety of Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa
Study Start Date : July 2007
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding

Arm Intervention/treatment
Active Comparator: A
Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.
Drug: Epoetin alfa
Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
Other Name: Procrit

Placebo Comparator: B
Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).
Drug: Saline
3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.

Primary Outcome Measures :
  1. Incidence of Adverse Events After Administering Intravenous Doses of Procrit® Once Daily for Three Consecutive Days to Patients With Aneurysmal SAH Before and After Vascular Clipping [ Time Frame: First 10 days following clipping and 6 week F/U ]
    Number of adverse events

Secondary Outcome Measures :
  1. To Determine if Administration of Procrit® Prior to Aneurysm Clipping Reduces the Incidence of Vasospasm Following a SAH Event Treated by Vascular Clipping. [ Time Frame: first 10 days following clipping and 6 week f/u ]
  2. To Determine if Procrit® Administration Prior to Aneurysm Clipping in Patients With Aneurysmal SAH Will Improve Neurological Assessment Scores in the Post-SAH/Post-clipping Time Period [ Time Frame: First 10 days following clipping and 6 week f/u ]
  3. To Determine the Feasibility of Organizing a Larger, Randomized Study to Explore the Neuroprotective Effect of Procrit® in Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) When Procrit® is Administered Prior to Surgical Clipping of the Aneurysm. [ Time Frame: When all data is collected and analyzed ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients age 30-75
  • Patients undergoing vascular clipping post SAH
  • Aneurysmal SAH as determined by history or clinical evaluation
  • WFNS Score I and II
  • Hb ≤ 12 g/dL within 36 hours prior to first dose of study drug
  • Patients who receive Study drug and undergo surgical clipping of the aneurysm within 36 hours of the SAH event

Exclusion Criteria:

  • Non-aneurysmal SAH
  • WFNS Score III and higher
  • Patients presenting with previous history of SAH
  • Terminal, brain-dead, comfort care patients
  • Patients not undergoing vascular clipping
  • Hb > 12 g/dL
  • Patients receiving blood transfusion prior to surgery
  • Patients who currently receive Procrit or an EPO product
  • Patients undergoing surgical clipping of the aneurysm greater than 36 hours after the SAH event
  • Pregnancy or lactating
  • Renal insufficiency (must present and maintain normal creatinine levels)
  • Uncontrolled hypertension (systolic > 150 mmHg)
  • Active or known seizure history within one year of SAH event
  • Known history of thrombotic vascular events (PE, DVT, AMI, stroke)
  • Allergy or sensitivity to mammalian derived products

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00626574

Layout table for location information
United States, Florida
Tampa General Hospital
Tampa, Florida, United States, 33606
Sponsors and Collaborators
University of South Florida
Ortho Biotech, Inc.
Layout table for investigator information
Principal Investigator: Enrico M Camporesi, MD University of South Florida

Layout table for additonal information
Responsible Party: Enrico Camporesi, Emeritus Professor, Dept of Surgery, University of South Florida Identifier: NCT00626574     History of Changes
Other Study ID Numbers: 105838c
USF 6176-P67638
First Posted: February 29, 2008    Key Record Dates
Results First Posted: October 29, 2012
Last Update Posted: July 31, 2018
Last Verified: July 2018

Keywords provided by Enrico Camporesi, University of South Florida:
Epoetin alfa
subarachnoid hemorrhage

Additional relevant MeSH terms:
Layout table for MeSH terms
Subarachnoid Hemorrhage
Intracranial Hemorrhages
Pathologic Processes
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Epoetin Alfa